Exploiting the tumor microenvironment for theranostic imaging

The integration of chemistry and molecular biology with imaging is providing some of the most exciting opportunities in the treatment of cancer. The field of theranostic imaging, where diagnosis is combined with therapy, is particularly suitable for a disease as complex as cancer, especially now that genomic and proteomic profiling can provide an extensive ‘fingerprint’ of each tumor. Using this information, theranostic agents can be shaped for personalized treatment to target specific compartments, such as the tumor microenvironment (TME), whilst minimizing damage to normal tissue. These theranostic agents can also be used to target multiple pathways or networks by incorporating multiple small interfering RNAs (siRNAs) within a single agent. A decade ago genetic alterations were the primary focus in cancer research. Now it is apparent that the tumor physiological microenvironment, interactions between cancer cells and stromal cells, such as endothelial cells, fibroblasts and macrophages, the extracellular matrix (ECM), and a host of secreted factors and cytokines, influence progression to metastatic disease, aggressiveness and the response of the disease to treatment. In this review, we outline some of the characteristics of the TME, describe the theranostic agents currently available to target the TME and discuss the unique opportunities the TME provides for the design of novel theranostic agents for cancer therapy. Copyright © 2011 John Wiley & Sons, Ltd.

[1]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[2]  J. Bussink,et al.  Changes in Blood Perfusion and Hypoxia after Irradiation of a Human Squamous Cell Carcinoma Xenograft Tumor Line , 2000, Radiation research.

[3]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[4]  J. Wallace.  Recent advances in gastric ulcer therapeutics. , 2005, Current opinion in pharmacology.

[5]  Chris A Flask,et al.  Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. , 2008, Biomaterials.

[6]  K. Polyak,et al.  Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast , 2009, Proceedings of the National Academy of Sciences.

[7]  M. Waltham,et al.  Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. , 2005, Cancer research.

[8]  A. Lascialfari,et al.  Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: a potential theranostic approach against cancer. , 2010, Small.

[9]  F. Vesuna,et al.  Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. , 2008, Cancer research.

[10]  C. Lewis,et al.  Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-21 , 2007, The Journal of Immunology.

[11]  R. Schilsky,et al.  Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward , 2010, Clinical Cancer Research.

[12]  Ick Chan Kwon,et al.  In vivo tumor diagnosis and photodynamic therapy via tumoral pH-responsive polymeric micelles. , 2010, Chemical communications.

[13]  Z. Bhujwalla,et al.  The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. , 2008, Neoplasia.

[14]  L. Naldini,et al.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. , 2007, Cancer research.

[15]  M. Neeman,et al.  Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. , 2005, Cancer research.

[16]  Z. Bhujwalla,et al.  Image-Guided Enzyme/Prodrug Cancer Therapy , 2008, Clinical Cancer Research.

[17]  G. Semenza.  HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. , 2009, Current pharmaceutical design.

[18]  J. Mcgiff,et al.  Arachidonic acid metabolism. , 1987, Preventive medicine.

[19]  D Artemov,et al.  Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA , 2009, Cancer Gene Therapy.

[20]  Jan Grimm,et al.  Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. , 2009, Small.

[21]  M. Pomper,et al.  Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. , 2010, Cancer research.

[22]  M J Bissell,et al.  Involvement of extracellular matrix constituents in breast cancer. , 1995, Seminars in cancer biology.

[23]  M. Coffey,et al.  Hypoxia response element‐driven cytosine deaminase/5‐fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro , 2009, The journal of gene medicine.

[24]  Brian O'Rourke,et al.  Hypoxic tumor microenvironments reduce collagen I fiber density. , 2010, Neoplasia.

[25]  Michal Neeman,et al.  Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. , 2005, Cancer research.

[26]  T. Hla,et al.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Ruth Nussinov,et al.  Nanoparticle-induced vascular blockade in human prostate cancer. , 2010, Blood.

[28]  M. Pittet.  Behavior of immune players in the tumor microenvironment , 2009, Current opinion in oncology.

[29]  Shelton D Caruthers,et al.  Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. , 2003, Cancer research.

[30]  Yi-Jen Chen,et al.  Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. , 2009, Biomaterials.

[31]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[32]  T. Scheenen,et al.  Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines , 2006, International journal of cancer.

[33]  S. Santra,et al.  Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. , 2010, Molecular pharmaceutics.

[34]  J. Bading,et al.  Integrin alpha v beta 3-targeted imaging of lung cancer. , 2005, Neoplasia.

[35]  Z. Bhujwalla,et al.  Silencing of Cyclooxygenase-2 Inhibits Metastasis and Delays Tumor Onset of Poorly Differentiated Metastatic Breast Cancer Cells , 2007, Molecular Cancer Research.

[36]  A. Richmond,et al.  Chemokines and chemokine receptors: new insights into cancer-related inflammation. , 2010, Trends in molecular medicine.

[37]  M. Neeman,et al.  Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. , 2006, Cancer research.

[38]  K. Mokbel,et al.  The role of cyclooxygenase-2 in breast cancer: review , 2008, Breast Cancer Research and Treatment.

[39]  S. Caruthers,et al.  Three‐dimensional MR mapping of angiogenesis with α5β1(αvβ3)‐targeted theranostic nanoparticles in the MDA‐MB‐435 xenograft mouse model , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Luting Xu,et al.  Human lupus T cells resist inactivation and escape death by upregulating COX-2 , 2004, Nature Medicine.

[41]  R. Weissleder,et al.  Optical Imaging of Spontaneous Breast Tumors Using Protease Sensing ‘Smart’ Optical Probes , 2005, Investigative radiology.

[42]  L. Tei,et al.  Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. , 2006, Cancer research.

[43]  Wolfhard Semmler,et al.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.

[44]  Wei Wang,et al.  Probing for Integrin αvβ3 Binding of RGD Peptides Using Fluorescence Polarization , 2005 .

[45]  Robert Jeraj,et al.  Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. , 2008, Physics in medicine and biology.

[46]  G. Schultz,et al.  Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[47]  S. Dubinett,et al.  The potential and rationale for COX-2 inhibitors in lung cancer. , 2006, Anti-cancer agents in medicinal chemistry.

[48]  R. DuBois,et al.  The role of prostaglandins and other eicosanoids in the gastrointestinal tract. , 2005, Gastroenterology.

[49]  T. Lawrence,et al.  New and Emerging Radiosensitizers and Radioprotectors , 2006, Cancer investigation.

[50]  Bruno Brochet,et al.  Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging , 2004, Investigative radiology.

[51]  R. DuBois,et al.  COX-2 inhibition and colorectal cancer. , 2004, Seminars in oncology.

[52]  Britton Chance,et al.  Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Schwab,et al.  Protons make tumor cells move like clockwork , 2009, Pflügers Archiv - European Journal of Physiology.

[54]  J. Bading,et al.  Integrin αβ3-Targeted Imaging of Lung Cancer , 2005 .

[55]  G. Semenza,et al.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.

[56]  Z. Bhujwalla,et al.  Inflammation, but not hypoxia, mediated HIF-1α activation depends on COX-2 , 2009 .

[57]  L. Jeng,et al.  Cyclooxygenase-2 enhances α2β1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells , 2010, Molecular Cancer.

[58]  R. Brueggemeier,et al.  Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. , 2006, Anti-cancer agents in medicinal chemistry.

[59]  H. Broxmeyer.  Chemokines in hematopoiesis , 2008, Current opinion in hematology.

[60]  L. Windsor,et al.  Matrix metalloproteinase dependent and independent collagen degradation. , 2006, Frontiers in bioscience : a journal and virtual library.

[61]  Arend Heerschap,et al.  Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy , 2005, Nature Biotechnology.

[62]  E. Skrzydlewska,et al.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. , 2005, World journal of gastroenterology.

[63]  H. Vogel,et al.  In Vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in an Orthotopic Glioblastoma Model , 2006, Molecular Imaging and Biology.

[64]  R. Gillies,et al.  Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? , 2007, Journal of bioenergetics and biomembranes.

[65]  Kai Chen,et al.  PET/NIRF/MRI triple functional iron oxide nanoparticles. , 2010, Biomaterials.

[66]  T. Petrova,et al.  Developmental and pathological lymphangiogenesis: from models to human disease , 2008, Histochemistry and Cell Biology.

[67]  Khaled M. Zaky,et al.  Phospholipases in biology and medicine. , 1990, Clinical biochemistry.

[68]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[69]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[70]  L. Peters,et al.  Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. , 1995, Cancer research.

[71]  M. Pagano,et al.  "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. , 1993, Biological chemistry Hoppe-Seyler.

[72]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[73]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[74]  Martin O Leach,et al.  Hyperpolarized 13C magnetic resonance detection of carboxypeptidase G2 activity , 2009, Magnetic resonance in medicine.

[75]  R. Qin,et al.  Effect of Antisense Hypoxia-inducible Factor 1&agr; on Progression, Metastasis, and Chemosensitivity of Pancreatic Cancer , 2006, Pancreas.

[76]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[77]  Z. Bhujwalla,et al.  Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. , 2009, Cancer biology & therapy.

[78]  Samuel Valable,et al.  In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma , 2007, NeuroImage.

[79]  Chong Li,et al.  N-Boc-histidine-capped PLGA-PEG-PLGA as a smart polymer for drug delivery sensitive to tumor extracellular pH. , 2010, Macromolecular bioscience.

[80]  Lawrence J Marnett,et al.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. , 2010, Cancer research.

[81]  P. Siegel,et al.  Emerging therapeutic targets in breast cancer bone metastasis. , 2010, Future oncology.

[82]  Mark W. Dewhirst,et al.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.

[83]  A. Ostman,et al.  Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. , 2009, Current opinion in genetics & development.

[84]  P. Michieli.  Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe? , 2009, Cell cycle.

[85]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[86]  J. Regan,et al.  EP1 Prostanoid Receptor Coupling to Gi/o Up-Regulates the Expression of Hypoxia-Inducible Factor-1α through Activation of a Phosphoinositide-3 Kinase Signaling Pathway , 2010, Molecular Pharmacology.

[87]  Genee Y. Lee,et al.  Targeting the tumor microenvironment. , 2007, Frontiers in bioscience : a journal and virtual library.

[88]  K. Alitalo,et al.  Lymphangiogenesis: Molecular Mechanisms and Future Promise , 2010, Cell.

[89]  N. Tamaki,et al.  Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression. , 2009, Nuclear medicine and biology.

[90]  Lisa M. Coussens,et al.  Immune cells as mediators of solid tumor metastasis , 2008, Cancer and Metastasis Reviews.

[91]  P. Allavena,et al.  Cellular and molecular pathways linking inflammation and cancer. , 2009, Immunobiology.

[92]  J. Yarnold,et al.  Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  F. Robert.  The potential benefits of low-molecular-weight heparins in cancer patients , 2010, Journal of hematology & oncology.

[94]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[95]  Wilson Mok,et al.  Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. , 2006, Cancer research.

[96]  Klaas Nicolay,et al.  MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[97]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[98]  J. Haeggström,et al.  Advances in eicosanoid research, novel therapeutic implications. , 2010, Biochemical and biophysical research communications.

[99]  Tae Gwan Park,et al.  Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells. , 2010, Biomaterials.

[100]  A. van Waarde,et al.  Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. , 2008, Nuclear medicine and biology.

[101]  Brenda Baggett,et al.  Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. , 2003, Biochemical pharmacology.

[102]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[103]  P. Allavena,et al.  Cancer related inflammation: the macrophage connection. , 2008, Cancer letters.

[104]  J. Griffiths.  Are cancer cells acidic? , 1991, British Journal of Cancer.

[105]  S. Saccani,et al.  Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.

[106]  Michal Neeman,et al.  In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. , 2007, Cancer research.

[107]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[108]  H. Vogel,et al.  In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. , 2006, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[109]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[110]  W. A. van der Donk,et al.  The cyclooxygenase reaction mechanism. , 2002, Biochemistry.

[111]  Brian Seed,et al.  Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.

[112]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[113]  W. Webb,et al.  Nonlinear magic: multiphoton microscopy in the biosciences , 2003, Nature Biotechnology.

[114]  R. Gillies,et al.  Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. , 2003, Biochemical pharmacology.

[115]  Dextran based pH-activated near-infrared fluorescence nanoprobe imaging the acidic compartments in cancer cells. , 2010, Chemical communications.

[116]  B. Krishnamachary,et al.  Hypoxia-induced human endonuclease G expression suppresses tumor growth in a xenograft model , 2008, Cancer Gene Therapy.

[117]  Jeff W M Bulte,et al.  Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.

[118]  Bonnie F. Sloane,et al.  Bicarbonate increases tumor pH and inhibits spontaneous metastases. , 2009, Cancer research.

[119]  Samuel Valable,et al.  In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma , 2008, NeuroImage.

[120]  Luigi Naldini,et al.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. , 2007, Blood.

[121]  Arvind P Pathak,et al.  Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. , 2006, Cancer research.

[122]  D. Artemov,et al.  Monitoring of release of cargo from nanocarriers by MRI/MR spectroscopy (MRS): Significance of T2/T  2* effect of iron particles , 2009, Magnetic resonance in medicine.

[123]  Naomi J Halas,et al.  A Molecularly Targeted Theranostic Probe for Ovarian Cancer , 2010, Molecular Cancer Therapeutics.

[124]  Mark W. Kieran,et al.  Identification of fibroblast heterogeneity in the tumor microenvironment , 2006, Cancer biology & therapy.